

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number  
**WO 02/054075 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/58,**  
33/532

(21) International Application Number: PCT/CA01/01815

(22) International Filing Date:  
18 December 2001 (18.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/258,387 28 December 2000 (28.12.2000) US  
09/905,907 17 July 2001 (17.07.2001) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 09/905,907 (CON)  
Filed on 17 July 2001 (17.07.2001)

(71) Applicant (for all designated States except US): MDS  
INC., doing business as MDS SCIEX [CA/CA]; 71 Four  
Valley Drive, Concord, Ontario L4K 4V8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARANOV,**

Vladimir [CA/CA]; 70 Peninsula Cr., Richmond Hill,  
Ontario L4S 1Z4 (CA). TANNER, Scott [CA/CA];  
184 Kemano Road, Aurora, Ontario L4G 4Z2 (CA).  
BANDURA, Dmitry [AU/CA]; 55 Wellington Street W.  
#318A, Aurora, Ontario L4G 4A3 (CA). QUINN, Zoe  
[CA/CA]; Apartment 913, 725 King Street West., Toronto,  
Ontario M5V 2W9 (CA).


(74) Agent: DONAHUE ERNST & YOUNG LLP; Ernst &  
Young Tower, T.D. Centre, Suite 1800, 222 Bay Street, Box  
197, Canada, Ontario M5K 1H6 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

[Continued on next page]

(54) Title: ELEMENTAL ANALYSIS OF TAGGED BIOLOGICALLY ACTIVE MATERIALS



(57) Abstract: Improved methods for the detection and quantitation of labeled biological materials in a sample using elemental spectroscopic detection are described. Element-labeled biologically active materials, comprising antibodies, antigens, growth factors, hormones, receptors and other biologically active materials covalently attached to a stable elemental tag, can be used in specific binding assays and measured by elemental spectroscopic detection. Also described are methods for the determination of metals in samples of interest using specific antibodies to isolate the target metals and elemental spectroscopy for detection and quantitation.

WO 02/054075 A1



**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## Elemental Analysis of Tagged Biologically Active Materials

### FIELD OF THE INVENTION

The present invention relates to methods for the detection and measurement of element tagged biologically active material and further relates to the detection and measurement of elements in a sample of interest. More particularly, the present invention is directed to detection and measurement of tagged immunoglobulins or antigens using an atomic mass or optical spectrometer having a source of atoms or atomic ions.

### BACKGROUND OF THE INVENTION

Various methods are in use for the detection and measurement of biological materials. To date, these determinations are generally facilitated through the use of radiological, fluorescent or enzymatic tags. None of these methods have successfully dealt with elemental tagging of biologically active materials, and in particular immunoglobulins and antigens, followed by detection using atomic mass or optical spectrometry.

The methods used to date have included (1) elemental tagging in immunoassays, (2) elemental tagging using radioisotopes, (3) elemental tagging to enhance fluorescence, (4) immunological detection of elemental species without tagging, and (5) direct elemental tagging for cell uptake studies. We will review each of these areas in turn.

5    *Elemental tagging in immunoassays*

Wang 1984 (US 4,454,233) disclosed the possibility of utilizing a mass spectrometer as a means of immunoassay detection. Wang's method required a cumbersome preliminary set of steps to first prepare a tagged 'mobile unit' which was then conjugated to an antibody/antigen. In the preferred embodiment, the 'mobile  
10    unit' was comprised of a latex particle embedded with heavy tagging elements such as Fe, Ni, Cu and Co. Among Wang's reasons for utilizing 'mobile units' were: (1) easy separation of bound reactant from unbound reactant, (2) simultaneous detection of many antigen/antibody complexes owing to the small size of mobile units, and (3) possible utilization of 'unstable' or 'reactive' tags, as tags embedded in the latex would  
15    not interfere with the reaction. However, due to the burdensome requirement of preparing mobile units, Wang's method was impractical and has not been used for immunoassay detection.

Immunoassay detection using element tagged immunoglobulins and antigens has also been possible using colloidal gold or extremely small beads of gold  
20    (several nanometers in diameter), for example NANOGOLD™ particles. Van Banchet and Heppelmann (1995), Wagenknecht et al. (1994), and Wenzel and Baumeister (1995) used colloidal gold to visualize protein structure in the cell and to detect receptor-ligand binding by electron microscopy. However, these assays suffer from lack of quantitation capabilities.

25    Element tagging has also been used in electrochemical immunoassays followed by polarographic detection of the generated complexes based on the catalytic conversion of a substrate by labeled metal ion or the anodic current of metal labeling Qiu and Song (1996). Similar to the preceding example, the assay lacked quantitation capabilities.

5

Thus, although elemental tagging has been used in immunoassays, the tagging methods have been cumbersome or were ineffective at quantitation.

*Elemental tagging using radioisotopes*

Historically, the most common use of elemental tagging has been the use of radioactive elements. While radioassays remain the method of choice due to their exceptional sensitivity to low levels of analyte, their general use is limited by the restrictions in dealing with radioactive materials.

10

*Elemental tagging to enhance fluorescence*

Recently, elemental tagging has been used to enhance luminescence of fluorescent tags. US 4,637,988 to Hinshaw et al., describes the use of lanthanide metals complexed with fluorescent compounds and chelating agents, that can be used in specific binding assays. U.S. 5,958,783 to Josel et al. describes the use of metal complexes with a charged linker as luminescent groups in fluorescence-based or electrochemiluminescence-based assays.

15

However, these fluorescent tagging methods suffer from the disadvantages associated with their relatively low sensitivity and resulting problems with quantitative analysis in samples containing low concentrations of target molecules. As well, fluorescence-based methods are limited to the analysis and quantification of only one or at most a few target substances per assay.

20

*Immunological Detection of elemental species*

25

Blake et al. (1998) and Darwish and Blake (2001) disclosed a method of detection and quantitation of elemental species by complexing elemental species with antibodies that recognize chelated elemental species, using antibodies conjugated

5 with fluorescent tags. However, as outlined above, fluorescence based assays suffer from low sensitivity and are limited to one or a few targets per assay.

*Direct elemental tagging in conjunction with gel electrophoresis*

Binet et al. (2001) disclosed a method of determining untagged proteins by separation using gel electrophoresis, followed by laser ablation of the  
10 separated spots and detection using mass spectrometry. However, this method has been limited to molecules that are naturally detectable by spectrometry.

Wind et al. (2001), Nagaoka and Maitani (2000) and Baldwin et al. (2001) used chromatography to separate proteins, followed by detection using mass spectrometry. Similarly, Chen et al, 2000 incorporated isotopic tags of  $^{13}\text{C}$ ,  $^{15}\text{N}$  and  
15  $^2\text{H}$  in proteins before chromatographic separation and detection using organic mass spectrometry. However, separation with chromatography is an added step, which can be onerous.

Thus, if one does not tag, one is limited to what is being assayed and using chromatography for separation adds a step to the process.

20 *Direct elemental tagging for cell uptake studies*

De Llano et al.(1996) and de Llano et al. (2000), disclosed a method of visualizing and measuring the uptake of low density lipoprotein (LDL) tagged with colloidal gold by cells using electron microscopy and mass/atomic spectrometry. However, the biological material was labeled directly and gel electrophoresis was not  
25 utilized.

Thus, various methods have been developed for visualizing and analyzing element tagged biologically active compounds. However, they have innate limitations, ranging from handling radioactive waste, to low sensitivity with

5 fluorescence based assays, to detection only capabilities, and to cumbersome preparation or separation steps.

An enormous potential exists for the development of very simple biological assays that take advantage of capabilities offered by elemental tagging coupled with elemental detection using a mass or optical spectrometer. Mass and  
10 optical spectrometry offer high sensitivity, accurate quantitation and a wide dynamic range. The use of elements to label biologically active material allows construction of an enormous number of distinguishable tags.

This invention involves bridging the science of biology, and in particular immunology, and analytical atomic mass spectrometry. The invention  
15 offers an easy and simple means of tagging biological molecules. Further, it offers excellent detection capabilities, equaling (or surpassing) the sensitivity of radioassays. It offers the safety of florescent based assays, and the added feature of an enormous number of available tags, with the possibility of simultaneous detection of numerous biological complexes. In addition, the handling of the reacted tagged complexes can  
20 be crude, as the integrity of the chemical complex need not be preserved in assaying the element.

### SUMMARY OF THE INVENTION

The last two decades have seen the improvement of elemental analysis  
25 due to the development of the inductively coupled plasma (ICP) source using mass or optical spectrometry. This has resulted in ultra sensitive spectrometers with high matrix tolerance and means of resolving isotopic and spectral interferences. The

5 present invention has coupled the developments in this field with the continuing need to provide rapid and precise detection and measurement in biological assays.

In its broad aspect, the present invention provides a simple method of tagging biologically active materials, and detecting and measuring the reactant complexes by an atomic mass or optical spectrometer. Variations of the invention  
10 include detection and measurement of elemental species by complexing antibodies to chelated elemental species, and detection and quantitation of an analyte by tagging the analyte directly.

In addition, the present invention allows one to use a large array of elemental tags to allow the simultaneous or sequential detection and measurement of  
15 biologically active material. This is known as "multiplexing".

According to one aspect of the present invention, there is provided a method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with one of an analyte and analyte complex, comprising: i) combining the tagged biologically active  
20 material with one of the analyte and analyte complex, ii) separating bound tagged biologically active material from unbound tagged material, and iii) detecting and measuring the bound tag elements by one of an atomic mass and optical spectrometer having a source of ions or atomic ions.

According to another aspect of the present invention there is provided a  
25 method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with one of an analyte and analyte complex, comprising: i) combining the biologically active material with one of the analyte and analyte complex, wherein the biologically active material binds a transition element, ii) introducing the transition element to the



- 5 sample, and iii) detecting and measuring the element by one of an atomic mass and optical spectrometer having a source of ions or atomic ions.

According to another aspect of the present invention, there is provided a method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with an analyte  
10 in the sample, comprising: i) directly tagging the biologically active material with a transition element, ii) combining the tagged biologically active material with the analyte in the sample where the biologically active material binds with the analyte, iii) separating bound tagged biologically active material from unbound tagged material, and iv) detecting and measuring the bound tag elements by one of an atomic mass and  
15 optical spectrometer having a source of atoms or atomic ions.

According to another aspect of the present invention, there is provided a method for the detection and measurement of an element in a sample, where a primary biologically active material binds with an analyte in the sample, and the measured element is a tag on a secondary biologically active material that binds to the  
20 primary biologically active material, comprising: i) combining the primary biologically active material with the analyte in a sample, where the primary biologically active material binds with the analyte, ii) separating bound biologically active material from unbound biologically active material, iii) directly tagging the secondary biologically active material with a transition element, iv) introducing the  
25 tagged secondary biologically active material into the sample where the secondary biologically active material binds with the primary biologically active material, v) separating bound tagged biologically active material from unbound tagged material, and vi) detecting and measuring the bound tag elements by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

5                   According to another aspect of the present invention, there is provided  
a method for the detection and measurement of an element in a sample, where a  
primary biologically active material binds with an analyte in the sample, and a  
secondary biologically active molecule binds with the primary biologically active  
material, and the measured element is a tag on a tertiary biologically active material  
10 that binds to the secondary biologically active material, comprising: i) combining the  
primary biologically active material with the analyte in a sample, where the primary  
biologically active material binds with the analyte, ii) separating bound biologically  
active material from unbound biologically active material, iii) introducing the  
secondary biologically active material in the sample, where the secondary biologically  
15 active material binds with the primary biologically active material, iv) separating  
bound biologically active material from unbound biologically active material, v)  
directly tagging the tertiary biologically active material with a transition element, vi)  
introducing the tagged tertiary biologically active material into the sample where the  
tagged tertiary biologically active material binds with the secondary biologically  
20 active material, vii) separating bound tagged biologically active material from  
unbound tagged material, and viii) detecting and measuring the bound tag elements by  
one of an atomic mass and optical spectrometer having a source of atoms or atomic  
ions.

                  According to another aspect of the present invention, there is provided  
25 a method for the detection and measurement of an element of an elemental species in  
a sample, where an antibody specific to the chelated elemental species binds to the  
chelated elemental species, comprising: i) chelating the elemental species,  
ii) introducing the antibody into the sample, iii) separating the antibody bound chelated  
elemental species complexes from the sample, and iv) detecting and measuring an

5 element of the elemental species contained in the removed complexes by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

According to another aspect of the present invention, there is provided a method for the detection and measurement of an element in a sample including an elemental species, where the measured element is a tag on an antibody specific to the  
10 chelated elemental species, comprising: i) chelating the elemental species, ii) tagging the antibody with a transition element, iii) introducing the tagged antibody into the sample where the tagged antibody binds with the chelated elemental species, iv) separating tagged antibody bound chelated elemental species from the sample, and v) detecting and measuring an element contained in the removed complexes by one of an  
15 atomic mass and optical spectrometer having a source of atoms or atomic ions. Variations of this aspect include measuring and detecting the element of the elemental species and measuring and detecting both the tag element and element of the elemental species.

According to another aspect of the present invention, there is provided  
20 a method for the detection and measurement of an element in a sample, where the measured element is a tag on an analyte in a sample, comprising: i) tagging the analyte with a transition element, ii) electrophorescing the sample containing the tagged analyte, and iii) detecting and measuring the tagged analyte by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

25 According to another aspect of the present invention, there is provided a method for the detection and measurement an element in a sample where the measured element is a tag on a biologically active material that binds with an analyte in a sample, comprising: i) binding the analyte with a biologically active material, wherein the biologically active material binds a transition element, ii)

5 electrophorescing the sample containing the tagged analyte, iii) introducing the transition element to the electrophoresced sample, and iv) detecting and measuring the element by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

According to another aspect of the present invention, there is provided  
10 a method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with an analyte in a sample, comprising: i) binding the analyte with the biologically active material, wherein the biologically active material binds a transition element, ii) introducing the transition element to the sample, wherein the element tags the biologically active  
15 material, and iii) detecting and measuring the element by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions. A preferred embodiment of this aspect is a method where the analyte is a cell.

According to another aspect of the present invention, there is provided  
a method for the detection and measurement of an element in a sample, where the  
20 measured element is a tag on a biologically active material that binds with an analyte in a sample, comprising: i) tagging the biologically active material with a transition element, ii) electrophorescing the sample containing the analyte, iii) introducing the tagged biologically active material into the sample containing the analyte, and iv)  
detecting and measuring the element by one of an atomic mass and optical  
25 spectrometer having a source of atoms or atomic ions.

According to another aspect of the present invention, there is provided  
a method for the detection and measurement of an element in a sample, where a  
primary biologically active material binds with an analyte in the sample, and the  
measured element is a tag on a secondary biologically active material that binds to the

5 primary biologically active material, comprising: i) electrophoresing the sample containing the analyte, ii) introducing the primary biologically active material into the sample where the primary biologically active material binds with the analyte, iii) tagging the secondary biologically active material with a transition element, iv) introducing the tagged secondary biologically active material into the sample, where  
10 the tagged secondary biologically active material binds with the primary biologically active material, and v) detecting and measuring the element by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

According to a preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described  
15 above, wherein the tagged biologically active material is a commercially available product.

According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described above, wherein the source of atoms or atomic ions is selected from a group consisting  
20 of inductively coupled plasma, graphite furnace, microwave induced plasma, glow discharge, capacitively coupled plasma, electrospray, MALDI and corona.

According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described above, wherein the source of atoms or atomic ions is an inductively coupled plasma  
25 source.

According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described above, wherein the step of detecting and measuring uses an optical spectrometer or a mass spectrometer.

5                   According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described above, wherein the element is an isotope or ion.

                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described  
10   above, wherein the element is selected from a group consisting of the noble metals, lanthanides, rare earth elements, gold, silver, platinum, rhodium, iridium and palladium.

                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described  
15   above, wherein the step of tagging involves covalently coupling the element to one of the biologically active material and analyte.

                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described above, wherein the biologically active material is selected from a group consisting of  
20   an antibody, antigen, hormone, growth factor, receptor, protein and nucleic acid.

                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described above, wherein the tag includes more than one element.

                  According to another preferred aspect of the present invention, there is  
25   provided a method of measurement and detection of any of the aspects described above, wherein the tag includes more than one isotope.

5                   According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described above, wherein the tag includes more than one atom of an isotope.

                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection of any of the aspects described  
10       above, wherein the tag includes a different number of atoms of each isotope.

                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection described in any of the aspects above comprising an additional step of introducing two or more biologically active materials or analytes having distinguishable elemental tags into a sample of interest  
15       for simultaneous determination.

                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection described in any of the aspects above comprising an additional step of sample introduction, wherein the sample introduction includes laser ablation.

20                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection described in any of the aspects above wherein the sample introduction includes laser ablation of polyacrylamide or agarose gels containing biologically active materials or analytes tagged by at least one element.

25                  According to another preferred aspect of the present invention, there is provided a method of measurement and detection described in any of the aspects above wherein the sample introduction includes laser ablation of polyacrylamide or

5 agarose gels containing biologically active materials or analytes tagged by atoms of at least one element having an un-natural isotopic composition.

According to another preferred aspect of the present invention, there is provided a method of measurement and detection described in any of the aspects above wherein the sample introduction includes laser ablation of animal tissue  
10 samples.

According to another preferred aspect of the present invention, there is provided a method of measurement and detection described in any of the aspects above wherein the sample introduction includes laser ablation of cell cultures.

According to another aspect of the present invention, there is provided  
15 a system of detection and measurement of molecules according to any of the aspects described above.

According to another aspect of the present invention, there is provided the use of one of an atomic mass and optical spectrometer for the detection and measurement an element described in any of the aspects above.

20 According to another aspect of the present invention, there is provided the use of one of an atomic mass and optical spectrometer for the detection and measurement of an elemental species described in any of the aspects above.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however,  
25 that the detailed description and the specific preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.



5

## BRIEF DESCRIPTION OF THE FIGURES

The invention will now be described in relation to the drawings in which

Figure 1 is a graph illustrating a calibration curve obtained by dilutions of human IgG and immunoreaction with the gold-labeled antihuman antibody with  
10 detection and quantitation using ICP-MS.

Figure 2 is graph showing the results of an immunoassay with human IgG and F'ab-Au, over a low concentration range with detection and quantitation using ICP-MS.

Figure 3 is a graph showing the results of an immunoassay with human  
15 IgG and F'ab-Au, over a high concentration range with detection and quantitation using ICP-MS.

Figure 4 is a bar graph showing the results of measuring endogenous protein in cultured cells with detection and quantitation using ICP-MS.

Figure 5 is a graph showing the detection and quantitation of a specific  
20 antigen by ICP-MS.

## DETAILED DESCRIPTION OF THE INVENTION

### DEFINITIONS

25

As used in this application:

"analyte" means any substance being identified and measured in an analysis, and includes but is not limited to elemental species, element

5 species chelate complexes; cells, viruses, subcellular particles; proteins including more specifically antibodies, immunoglobulins, lipoproteins, glycoproteins, peptides, polypeptides; nucleic acids including DNA and RNA; and including peptidic nucleic acids; oligosaccharides, polysaccharides, lipopolysaccharides; cellular metabolites, haptens, hormones, pharmacologically active substances, alkaloids, steroids, vitamins, amino acids and sugars.

"**analyte complex**" means an analyte bound to other molecules or biologically active materials.

"**animal**" means all members of the animal kingdom.

15 "**atomic mass spectrometer**" means a mass spectrometer that generates atomic ions, and detects atomic ions based on the mass/charge ratio.

"**biologically active material(s)**" means any biological substance found in nature and includes cells, viruses, subcellular particles; proteins including more specifically antibodies, immunoglobulins, lipoproteins, glycoproteins, peptides, polypeptides; nucleic acids including DNA and RNA, and including peptidic nucleic acids; oligosaccharides, polysaccharides, lipopolysaccharides, cellular metabolites, haptens, hormones, pharmacologically active substances, alkaloids, steroids, vitamins, amino acids and sugars.

25 "**capacitively coupled plasma**" (CCP) means a source of ionization in which a plasma is established by capacitive coupling of

5 radiofrequency energy at atmospheric pressure or at a reduced pressure (typically between 1 and 500 Torr) in a graphite or quartz tube

"corona" means a source of ionization in which a conductor (typically a needle) is provided a voltage relative to a counter electrode surface (typically containing an ion sampling aperture) such that the voltage  
10 gradient exceeds a critical value to cause ionization of the surrounding gas, but not sufficient to cause sparking.

"elemental species" means a molecule containing a metal bound to another atom or group of atoms. For example, selenite ( $\text{SO}_3^{-2}$ ),  
15 selenate ( $\text{SO}_4^{-2}$ ), methylselenocysteine and selenomethionine are elemental species of selenium.

"element tagged" means a molecule tagged with a transition element, including a noble metal or lanthanide.

"elemental tag" means any transition element, including a noble metal or lanthanide, used to tag the biologically active material or  
20 analyte.

"electrospray" means a source of ionization in which a liquid sample is nebulized from a tube due to the sufficiently high potential applied, which also provides a charge to the droplet, and in which the resultant  
25 charged droplet evaporates and fragments yielding small charged droplets or charged molecular ions.

"Fab" means the antigen binding fragment of an antibody obtained by papain reaction with immunoglobulin.

5           **"Fab"** means the antigen binding fragment of an antibody. Fab' is obtained by pepsin reaction with immunoglobulin, followed by cleavage of two disulfide bonds.

**"Glow discharge" (GD)** means a source of ionization in which a discharge is established in a low pressure gas (typically between 0.01  
10           and 10 Torr), typically argon, nitrogen or air, by a direct current (or less commonly radiofrequency) potential between electrodes.

**"graphite furnace"** means a spectrometer system that includes a vaporization and atomization source comprised of a heated graphite tube. Spectroscopic detection of elements within the furnace may be  
15           performed by optical absorption or emission, or the sample may be transported from the furnace to a plasma source (e.g. inductively coupled plasma) for excitation and determination by optical or mass spectrometry.

**"inductively coupled plasma"(ICP)** means a source of atomization and ionization in which a plasma is established in an inert gas (usually  
20           argon) by the inductive coupling of radiofrequency energy. The frequency of excitation force is in the MHz range.

**"lanthanide"** means any element having atomic numbers 58-71. They are also called rare earth elements.

25           **"MALDI"** means a source of ionization (Matrix Assisted Laser Desorption Ionization) in which ions are produced from a sample mixed with a matrix (typically analyzed in crystalline form) by exposure to laser irradiation, typically at low pressure

5                   **"mass spectrometer"** means an instrument for producing ions in a gas and analyzing them according to their mass/charge ratio.

**"microwave induced plasma" (MIP)** means a source of atomization and ionization in which a plasma is established in an inert gas (typically nitrogen, argon or helium) by the coupling of microwave  
10                   energy. The frequency of excitation force is in the GHz range.

**"multiplexing"** means using more than one elemental tag for the simultaneous or sequential detection and measurement of biologically active material.

**"noble metal"** means any of several metallic elements, the  
15                   electrochemical potential of which is much more positive than the potential of the standard hydrogen electrode, therefore, an element that resists oxidation. Examples include palladium, silver, iridium, platinum and gold.

**"optical spectrometer"** means an instrument calibrated to measure  
20                   either wavelength of light or the refractive index of a prism, and includes atomic emission and atomic absorption spectrometers.

**"plasma source"** means a source of atoms or atomic ions comprising a hot gas (usually argon) in which there are (approximately) equal numbers of electrons and ions, and in which the Debye length is small  
25                   relative to the dimensions of the source.

**"rare earth metals"** means any element having atomic numbers 58-71. They are also called "lanthanides".

5                   **"sample"** means any composition of liquid, solid or gas containing or suspected of containing an analyte.

**"transition element"** means any element having the following atomic numbers, 21-29, 39-47, 57-79, and 89. Transition elements include the rare earth elements, lanthanides and noble metals. (Cotton and  
10                   Wilkinson, 1972, pages 528-530).

There are a number of aspects to the present invention.

                  The first aspect involves labeling of biologically active material which  
15       binds to an analyte in a sample. Most often, the biologically active material would be an immunoglobulin or antigen. The element is detected by an atomic mass or optical spectrometer having a source of atoms or atomic ions. Examples 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 15 and 16 describe this aspect of the invention in more detail.

                  The individual steps involved in this first aspect of the invention are  
20       known to those skilled in the art but the coupling of immunoassays with spectrometry is new and inventive. Each of the individual steps is described in Materials and Methods section of this application.

                  The benefits of this aspect of the invention are that: (1) it allows for the detection of minute quantities of analyte, (2) it allows for multiplexing, saving  
25       time, resources and providing for a better analysis of the sample, (3) the analysis is very rapid as there is no need to wait for enzymatic reactions, and measurement time by ICP-OES/MS is shorter than radiological tag measurement, (4) it has a large dynamic range, (5) radioisotopes are not required, producing a safe work environment

5 and avoids toxic waste, and (6) the reacted complex does not need to be preserved, allowing the use of acidic media to degrade the complex and stabilize the element in solution and thereby increasing the period of storage of the sample before analysis.

The second aspect involves the determination of elemental species. In cases where mass spectrometry can not differentiate elemental species, the use of  
10 antibodies to detect elemental species coupled with mass spectrometry allows for their differentiation. Examples 11, 12 and 13 describe this aspect of the invention in more detail. In this aspect, as show in Example 13, multiplexing can be used. Again, the benefits of this aspect are that: (1) it allows for the detection of minute quantities of analyte, (2) it allows for multiplexing, (3) the analysis is very rapid, (4) there is a large  
15 dynamic range, (5) one can avoid the use of radioisotopes, (6) the reacted complexes do not need to be preserved, and (7) chromatographic separation is not required, which speeds up and simplifies the analysis.

The third aspect is the direct labeling of the analyte. The individual steps involved in this third aspect are known to those skilled in the art, but direct  
20 labeling coupled with mass spectrometry is new and inventive. Example 17 describes this third aspect of the invention. A variation of this aspect is described in Example 9. Again, the benefits of this third aspect are that: (1) it allows for the detection of minute quantities of analyte, (2) it allows for multiplexing, (3) the analysis is very rapid, (4) there is a large dynamic range, (5) one can avoid the use of radioisotopes,  
25 (6) the reacted complexes do not need to be preserved, and (7) chromatographic separation is not required, which speeds up and simplifies the analysis.

For all aspects of the invention, it is understood that the biologically active material can be added to the analyte, or the analyte can be added to the biologically active material. Further, an analyte complex can be formed, by the

- 5 binding of molecules to the analyte, as seen in the examples outlined below, in which a series of antibodies (primary, secondary, tertiary) can be conjugated to the analyte.

### *Tagging Elements*

The choice of the element to be employed in the methods of the present invention is preferably selected on the basis of its natural abundance in the sample  
10 matrix under investigation. In order to achieve selectivity, specificity, the ability to provide reproducible results, and include appropriate standards for accurate quantitation, it is evident that the tagging element should be of low natural abundance. For example, in a preferred embodiment, the rare earth elements or gold can be used as tag materials. Yet, in another embodiment, an unusual isotope composition of the  
15 tag can be used in order to distinguish between naturally present elements in the sample and the tag material. In this case non-radioactive isotopes of, for example, iron, potassium, nickel or sodium can be successfully distinguished from naturally abundant isotopes employing the elemental analysis.

The size of an elemental tag (ratio of atoms which are detectable by  
20 means of the elemental analysis to the each antigen-antibody conjugate) may be varied in order to produce the most consistent, sensitive and quantitative results for each particular set of antigens and antibodies.

In a preferred embodiment of this invention, several conjugates can be used in one sample simultaneously providing that the tagging material was selected to  
25 be different in every assay. In this embodiment the preferred ICP-MS technique is used in order to quantify different tagging elements simultaneously or sequentially depending on the apparatus employed.



5                   Although many applications of the present method will involve the use of a single elemental tag for each antibody or antigen, it should be readily appreciated by those skilled in the art that an antibody or antigen may be tagged with more than one element. As there are more than 80 naturally occurring elements having more than 250 stable isotopes, there are numerous elements, isotopes and combinations thereof to choose from.. For example, there are 20 distinguishable 3-atom tags that may be constructed from only 4 different isotopes, and one million distinguishable 15-atom tags that may be constructed from 10 different isotopes, or 70-atom tags that may be constructed from 5 different isotopes. Within limits prescribed by the need to have distinguishable tags when in combination, this will allow for simultaneous  
15   detection of numerous biologically tagged complexes. It is advantageous if the relative abundance of the tag elements is sufficiently different from the relative abundance of elements in a given sample under analysis. By "sufficiently different" it is meant that under the methods of the present invention it is possible to detect the target antibody or antigen over the background elements contained in a sample under  
20   analysis. Indeed, it is the difference in inter-elemental ratios of the tagged antibody or antigen, and the sample matrix that can be used advantageously to analyze the sample.

It is feasible to select elemental tags, which do not produce interfering signals during analysis. Therefore, two or more analytical determinations can be performed simultaneously in one sample. Moreover, because the elemental tag can be  
25   made containing many atoms, measured signal can be greatly amplified.

#### ***Detection of Metal Ions and elemental species***

As was indicated above, an important application of the method of the present invention is the detection of metal in samples, such as toxic metals in environmental settings, including organisms, animals, and humans. Preferably, the

5 invention detects metals in environmental settings. However, as is readily apparent to those skilled in the art, the toxicity of metals depends on the oxidation state, and often on the chemical structure of the elemental species. While an elemental detector, such as uses an ICP source, is able to determine the total quantity of an element in a sample it is generally unable to distinguish different species. There is an ongoing attempt to  
10 use different forms of chromatography to pre-separate the sample before the ICP, but this approach has been plagued with concern about the integrity of the sample, i.e., preservation of the oxidation state during sample preparation. The method of the present invention provides a means by which a long-standing problem of detecting speciation is overcome.

15 In a further embodiment of the present invention, there is provided a method of determining the concentration of a metal ion of interest, preferably toxic metals, more preferably in environmental/biological samples, comprising preparing an antibody which is specific to a selected speciation state of a given toxic metal, reacting said antibody with a solution suspected of containing a toxic metal, and  
20 detection of the resulting complexes by application of ICP- MS. Methods for the preparation of an antibody which is specific to a selected oxidation state of a given toxic metal are known by those skilled in the art and are described, for examples, in Bosslet et al.(1999), Blake et al. (1998), and Bordes et al. (1999).

In a further embodiment of the present invention, a tagged antibody is  
25 added to a sample containing a speciated element. The sample is split into two halves. The first half of the sample is analyzed for total speciated element. In the second half of the sample, the reacted complexes are separated from the unreacted. The tagging element and the speciated element are quantified in the reacted sample. The speciated element is also quantified in the unreacted sample. In this instance, the

5 results will provide complementary data, and the fraction of the specific species in question will be determined.

As was also indicated above, an important application of the method of the present invention is the detection of elements of tags in samples by means of laser ablation of polyacrylamide gels where tagged molecules are separated by  
10 electrophoresis. This application can be used in order to analyze biomolecules in gels rapidly without destroying the sample. Also, by employing microablation it is feasible to distinguish cancerous cells from normal cells on histological section of biopsy samples using element-tagged antibodies specifically attached to the markers of cancerous populations.

15 The following section describes the methods and materials required to carry out the following invention.

## METHODS AND MATERIALS

### *ICP-MS Techniques*

20 Techniques using ICP-MS or OES can be applied for the purposes of this invention.

For example, in its latest realization it was described in Tanner et al.(2000a), Baranov et al. (1999), Tanner et al. (1999), Tanner et al. (2000b), and Bandura *et al.* (2000). This successful modification of ICP-MS includes the dynamic reaction cell, which is  
25 used in order to reduce isobaric interferences in atomic mass spectrometry. Briefly, the ICP-DRC-MS technique comprises a high temperature plasma in which the sample particles are atomized and ionized; vacuum interface which is designed to transport the plasma together with analyte ions from atmospheric pressure to vacuum;

- 5 ion focusing optics; the dynamic reaction cell for chemical modification of the ion current and mass analyzing devise (quadrupole, TOF or magnetic sector). The sample is usually introduced to the plasma as a spray of droplets (liquid sample) or flow of particles (laser ablation of solid surfaces).

*Sources of atoms and atomic ions*

- 10 The source of atoms or atomic ions can be produced from the following sources: inductively coupled plasma (ICP), graphite furnace, microwave induced plasma (MIP), glow discharge (GD), capacitively coupled plasma (CCP), electrospray, MALDI or corona.

*Antibody Preparation*

- 15 According to a preferred embodiment of the methods of the present invention, elementally tagged antibodies, or antibodies directed to a metal of interest are employed. Antibodies that bind a target of interest can be prepared using techniques known in the art such as those described by Kohler and Milstein (1975), Wakabayashi et al. (1990), Frackelton et al. (1985) and Gillis (1983), which are incorporated herein  
20 by reference. (See also Kennett, McKearn, and Bechtol (1980), and Harlow and Lane (1988), which are also incorporated herein by reference).

- Within the context of the present invention, antibodies are understood to include monoclonal antibodies, polyclonal antibodies, antibody fragments (e.g., Fab, and F(ab')<sub>2</sub>) and recombinantly produced binding partners. Antibodies are  
25 understood to be reactive against the target antigen if they bind to the target with an affinity of greater than or equal to 10<sup>-6</sup> M.

## 5 *Tagging of Biologically Active Materials*

Preferably, the tagging element is in the form of a nanoparticle, which is attached to a biologically active material, such as for example an antibody, without degrading its activity (tagged conjugate). Examples of techniques for coupling elemental tags to biologically active materials are well known to those skilled in the art. For example, Barlett, P. A. et al. (1978), describe a metal cluster compound (Au<sub>11</sub>) having a core of 11 gold atoms with a diameter of 0.8 nm. The metal core of 11 gold atoms in the undecagold metal cluster compound is surrounded by an organic shell of PAR<sub>3</sub> groups. This metal cluster compound has been used to form gold immunoprobes, for example, by conjugating Au<sub>11</sub> to Fab' antibody fragments as well as other biological compounds.

Another metal cluster compound which has been used as a probe is Nanogold<sup>TM</sup>. Nanogold<sup>TM</sup> has a metal core with 50-70 gold atoms (the exact number not yet being known but believed to be 67 gold atoms) surrounded by a similar shell of organic groups (PAR<sub>3</sub>) as undecagold. The metal core of Nanogold<sup>TM</sup> is 1.4 nm in diameter.

A more recent description of techniques for the preparation of biological tags which may be used in the method of the present invention is found in Hainfeld *et al.* (1996) (US 5,521,289). Briefly Hainfeld *et al.* (1996) describes, among others, thiol gold clusters produced by forming an organic-gold complex by reacting a compound containing a thiol with gold in solution. A second equivalent is also added of the thiol compound. Finally the gold organic is reduced with NaBH<sub>4</sub> or other reducing agents and organometallic particles are formed. These have the general formula Au<sub>n</sub> R<sub>m</sub> R'<sub>l</sub> . . . , where n, m, and l are integers, R and R' are organic thiols,

5 (e.g., alkyl thiols, aryl thiols, proteins containing thiol, peptides or nucleic acids with thiol, glutathione, cysteine, thioglucose, thiolbenzoic acid, etc.). With two equivalents of organic thiol compound, clusters with gold cores ~1.4 nm are formed with many organics. The organic moiety may then be reacted by known reactions to covalently link this particle to antibodies, lipids, carbohydrates, nucleic acids, or other molecules  
10 to form probes. Mixtures of organic thiols may be used to provide mixed functionality to the clusters. These organo-gold clusters are stable to heating at 100 degrees C.

These organic thiol-gold preparations may also be made using similar processes with alternative metals to gold, e.g., platinum, silver, palladium and other metals, or mixtures of metal ions, e.g., gold and silver, resulting in mixed metal  
15 clusters. The metal clusters together with all other components of a sample are readily atomized and ionized in the high temperature ICP for subsequent MS or OES analysis.

### *Separation Techniques*

According to one embodiment of the present invention, a tagged  
20 conjugate may be isolated for analysis by employing a filtration technique. For example, after incubation of an antigen with the tagged conjugate the sample undergoes filtering through a size separating centrifugal filter. Non-reacted tagged antibody together with other components of the sample mixture including non-reacted antigen pass into the filtrate. Complexes of antigen and antibody conjugate are left on  
25 the filter and after washing out can be stabilized in acidic solution. Since the integrity of the sample (i.e. the chemical form) is not important after separation, the separated sample can be acidified/degraded/stabilized (for example in acidic media) and quantitative analysis is preferably carried out using the ICP-MS technique. The optimal concentrations of all reagents for each system should be determined in an

5 initial criss-cross serial dilution experiment and the concentration of reagent being quantitated must lie within the dynamic range of the standard curve. As will be readily apparent to those skilled in the art, other techniques of separation of free substance or non-complexed proteins from complexed substance may be used, for examples, salting out, chromatography, electrophoresis, gel filtration, fractionation,  
10 absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof.

In light of the present disclosure, those skilled in the art will readily appreciate other methods and applications of the methods of the present invention.

The examples below are non-limiting and are merely representative of  
15 various aspects and features of the present invention.

## EXAMPLES

### Example 1. Nanogold<sup>TM</sup> immunoassay

The following provides an example of the methods of the invention using the  
20 Nanogold-IgG<sup>TM</sup> (or Nanogold-Fab'<sup>TM</sup>; Nanoprobes) immunoassay and its protocol. PBS buffer A is prepared as follows: 150mM NaCl; 20mM phosphate, pH 7.4; 1% BSA (bovine serum albumin). All eppendorf tubes, micro-titer plates, and filters to be used subsequently are pacified with PBS buffer A for 1 hour at room temperature. This treatment will reduce the non-specific interactions that occur between the plastic  
25 used and the antigen and Nanogold-IgG<sup>TM</sup>. Alternatively low retention plastic products can be used (e.g. Axygen tubes). Following this a solution of the antigen (peptide, protein, etc.) in the concentration range of 1000 to 0.5 pg/ $\mu$ l in PBS buffer A is prepared. All dilutions are stored on ice. Subsequently, 100ul of either antigen

5 solution or PBS buffer A (for controls) is pipetted into the individual wells of the micro-titer plate (or set of eppendorf tubes). The Nanogold-IgG<sup>TM</sup> is pre-filtered through 300KDa (MICRCON<sup>TM</sup> or Centricon<sup>TM</sup>) centrifugal filter devices. Dilutions of filtered Nanogold-IgG<sup>TM</sup> in PBS buffer A are prepared as follows: A 1:50 dilution is produced by adding 60µl of Nanogold-IgG<sup>TM</sup> in 2940µl PBS buffer A. A 1:500  
10 dilution is then produced by adding 100µl of Nanogold-IgG<sup>TM</sup> to 900µl of PBS buffer A. Depending on concentration range of antigen, 100 to 500 µl of 1:500 Nanogold-IgG<sup>TM</sup> is then added to the wells of the plate and then incubated for 1-2 hours at room temperature. The total amount of antigen- Nanogold-IgG<sup>TM</sup> mix is then pipetted into the sample reservoir (upper chamber) of a 300KDa MICROCON<sup>TM</sup> centrifugal filter  
15 device (max volume 2ml). This sample is centrifuged at 14,000g for 15 minutes at room temperature. The assembly is removed from the centrifuge and the vial separated from sample reservoir. The sample reservoir is inverted in a new vial, and spun for 3 minutes at 1000g to transfer the concentrate to a new vial. Finally, a fixed volume of the collected antigen-Nanogold-IgG<sup>TM</sup> antibody mixture is diluted to 1ml  
20 with 10%HCl/1ppbIr for stabilization. Ir provides an internal standard for ICP-MS quantitation and the acid solution is suitable for the elemental analysis. The linearity of the ICP-MS detector response as a function of the concentration of the analyte human IgG is shown in the results presented in Figure 1.

**Example 2. Immunoassay, other than Nanogold-IgG<sup>TM</sup>.**

25 According to this example, an antibody is tagged with an element (eg. Eu, Ru, etc.) suitable for analysis by ICP-MS and is introduced into a sample containing antigens of interest (e.g. human blood proteins). The element-tagged antibody reacts specifically to the target antigen. The resulting tagged antigen-antibody complex is



5 separated from un-reacted antibody (as in Example 1, 3, 4, 5, 8, 9, or 10), and the tagged complex is analyzed by ICP-MS. Variations of this example include:

- a) Tagging with multiple atoms to amplify the signal and thereby improving detectability.
- b) As, a), except the tag contains several isotopes of the same element or  
10 different elements, preferably in a non-natural (unusual) distribution, so that the unique isotope distribution is a determinant of the targeted antigen. It is to be recognized that there are more than 80 naturally occurring elements) of which some 60 may have value in this application) having more than 250 stable isotopes. This allows construction of an enormous number of  
15 distinguishable tags. For example, there are 20 distinguishable 3-atom tags that may be constructed from only 4 different isotopes, and one million distinguishable 15-atom tags from 10 different isotopes, or 70-atom tags from 5 different isotopes.
- c) As in a) and b), but incorporating different antibodies with specificity to  
20 different target molecules, to allow simultaneous determination of different target molecules. The number of simultaneous determinations is limited by the number of distinguishable tags in combination (which is fewer than the number of distinguishable tags in isolation as described above).

### **Example 3. Protein A Sepharose Immunoassay**

25 The following provides an example of the methods of the invention using the Protein A Sepharose CL-4B™ (Pharmacia) immunoassay and its protocol. Either Nanogold-Fab'™ or another element-labeled Fab' specific to the target protein (or

5 host species of the secondary antibody) may be used. There are two types of immunoassays that may be used:

a) Direct immunoassay, which would involve trapping the target protein of interest (protein X) by incubating Protein A Sepharose CL-4B™ with an excess of antibody specific to the target protein, washing off the un-reacted  
10 antibody, adding the protein sample, washing off the unbound protein, and then exposing the PAS-antibody-protein X complexes to element-labeled, anti-X Fab'.

b) Indirect immunoassay, which would involve trapping the target protein of interest (protein X) by incubating Protein A Sepharose CL-4B™ with an  
15 excess of primary antibody (e.g. polyclonal) specific to the target protein, washing off the un-reacted primary antibody, adding the protein sample, washing off the unbound protein, and then exposing the PAS-antibody-protein X complexes to a second antibody specific to protein X (e.g. a monoclonal antibody), washing off un-reacted secondary antibody, and then incubating the  
20 PAS-antibody-protein X-antibody complexes with an element-labeled, anti-secondary Fab'. Alternatively beads or micro-titer plates covalently bound to anti-protein X antibodies may be used.

PBS buffer A is prepared as follows: 150mM NaCl; 20mM phosphate, pH 7.4; 1% BSA (bovine serum albumin). All eppendorf tubes, micro-titer plates, and filters, and  
25 slurry of Protein A Sepharose CL-4B™ to be used subsequently are pacified with PBS buffer A for 1 hour at room temperature. This treatment will reduce the non-specific interactions that occur between the plastic used and the antigen and Nanogold-Fab'™. Alternatively low retention plastic products can be used (e.g. Axygen tubes). Following this a solution of the antigen (peptide, protein, etc.) in the concentration

5 range of 1000 to 0.5 pg/ $\mu$ l in PBS buffer A is prepared. All dilutions are stored on ice. Subsequently, 100 $\mu$ l of either antigen or PBS buffer A (for controls) is pipetted into the individual wells of the micro-titer plate (or set of eppendorf tubes). The Nanogold-Fab'<sup>TM</sup> is pre-filtered through 300KDa MICRCON<sup>TM</sup> (or Centricon<sup>TM</sup>) centrifugal filter devices. Dilutions of filtered Nanogold-Fab'<sup>TM</sup> in PBS buffer A are  
10 prepared as follows: A 1:50 dilution is produced by adding 60 $\mu$ l of Nanogold-Fab'<sup>TM</sup> in 2940 $\mu$ l PBS buffer A. A 1:500 dilution is then produced by adding 100 $\mu$ l of Nanogold-Fab'<sup>TM</sup> to 900 $\mu$ l of PBS buffer A. Depending on concentration range of antigen, 100 to 500  $\mu$ l of 1:500 Nanogold-Fab'<sup>TM</sup> is then added to the wells of the plate and then incubated for 1-2 hours at room temperature. The sample is  
15 centrifuged at 14,000rpm for 2 minutes at room temperature. The beads are washed four times with PBS buffer A. In method b) the additional steps to include consist of washing off un-reacted monoclonal antibody, and then incubating the PAS-antibody-protein X-antibody complexes with an element-labeled, anti-X Fab'. Finally, a fixed volume of 10%HCl/1ppbIr is added to each well. It provides an internal standard for  
20 ICP-MS quantitation and the acid solution is suitable for the elemental analysis.

Experimental results obtained according to method a) are given in Figures 2 and 3, using human IgG as the analyte with F'ab-Au as the tagged antibody. Figure 2 provides the calibration results over a relatively low concentration range, and Figure 3 over a higher concentration range. Together, the data exhibit greater than 2 orders of  
25 magnitude of detector linearity with respect to the analyte concentration.

This Example also permits multiplexing to be analyzed and can be used to identify protein-protein interactions. In this method, cell lysate is collected and subjected to the method as above where an interaction is suspected between protein A and protein B. In this case the primary antibody would be specific to protein A and an element-

- 5   labeled Fab' would be specific to protein B. Interactions with multiple other proteins (e.g. protein C and protein D) could be detected at the same time, providing that different elements were used to label anti-Fab' specific to protein C and anti-Fab' specific to protein D.

**Example 4. Dynabeads™ Immunoassay**

- 10       The following method provides an example of the invention using the Dynabeads™ (Dyna) immunoassay and its protocol. This immunoassay is performed as in Example 3, using Dynabeads™ in place of Protein A Sepharose CL-4B™. Instead of centrifuging the sample, the sample is exposed to a magnetic device (Dyna MPC™). This draws the beads to the bottom of the wells between and after each
- 15   wash step. Again, 10%HCl/1ppbIr is added to each well in the final step to provide an internal standard for ICP-MS quantitation and elemental analysis.

In the same manner as described for Example 3, multiplexing and protein-protein interactions can be identified using this method.

**Example 5. Method for detection and quantification of endogenous proteins in**

20   **cultured cells.**

There are two methods by which the discrete changes in the levels of endogenous proteins in culture cells can be measured.

- a) Direct immunoassay, in which an antibody specific to the protein of interest is required. This antibody is labeled with an element suitable for analysis by
- 25   ICP-MS.
- b) Indirect immunoassay, in which an antibody (primary antibody) specific to the protein of interest is required. In addition a secondary antibody specific to the primary antibody is labeled with an element suitable for analysis by ICP-MS.

5 A mono-layer of attached cultured cells is grown and treated with conditions of interest. The growth media is removed and the cells are washed with 1xPBS three times. PBS is then replaced with ice-cold methanol and the culture dishes are incubated at  $-20^{\circ}\text{C}$  for 5 minutes. The methanol is removed and the cells are allowed to dry completely. A blocking buffer (e.g. 10% horse serum, 1% BSA, 0.05% Tween-  
10 20, 1xPBS) is added to the culture dishes and the dishes are incubated for 1-2 hours at room temperature. In method a) an antibody specific to the protein of interest is labeled with an element, diluted in blocking buffer and added to the culture dishes. The cells are exposed to the antibody mix for 2 hours at room temperature (or  $37^{\circ}\text{C}$ ). During this time, the element-tagged antibody binds the target protein through its tail.  
15 In method b) the antibody specific to the protein of interest is not labeled. In the next step, the un-reacted primary antibody is washed away with blocking buffer. In method b) the element-labeled secondary antibody is diluted in blocking buffer and applied to the cells. The dishes are incubated for 1-2 hours at room temperature. The un-reacted secondary antibody is then washed away with blocking buffer. Finally, in  
20 both methods, an acid solution (e.g. concentrated HCl) is added, to release and dissolve the tagging element. The dissolved element in acid is diluted with 10% HCl/1ppb Ir to provide an internal standard. The acid solution containing the tagging element is then analyzed by ICP-MS to quantify the protein of interest.

Experimental data obtained according to method b) is shown in Figure 4. This data  
25 examines the sensitivity of this immunoassay, by comparing the relative amounts of Smad2 in three different cell cultures; COS (Bars 5 and 6), COS transfected with pCMV5B-Smad2 (COS-smad2) (Bars 1 and 2), and C2C12 cells (Bars 3 and 4). COS cells are known to have undetectable levels of Smad2 protein (using Western blot analysis). Conversely, Smad2 is detectable in C2C12 cell lysate and in COS cells that

5 have been transfected with pCMV5B-Smad2. These cell cultures are prepared in 60mm dishes, fixed with methanol, blocked with TBST buffer and then incubated in either the presence (Bars 2, 4, and 6) or absence (Bars 1, 3, and 5) of polyclonal anti-Smad2 antibody (Upstate Biotech). Cells are incubated with a gold-tagged anti-rabbit antibody (Nanoprobes), dissolved in concentrated HCl, diluted 2 fold in  
10 10%HCl/1ppb-Ir and analyzed using the ICP-MS. Each bar is an average of triplicate samples. Bars 1, 3, and 5 reflect negative control cultures not treated with primary antibody (-+). Cultures treated with both primary and secondary antibodies (++) show that in the two cell cultures that express smad2, a substantial increment in the signal over the (-+) results indicates the presence of the smad2 protein. The third culture,  
15 COS, which is not expected to express smad2, shows a signal for the (++) case that is roughly comparable to that of the blank (-+).

**Example 6. Method for determination efficiency of cell transfection.**

The effectiveness of cell culture transfection is determined by first modifying cells to transduce a tail (e.g. FLAG<sup>TM</sup>). As in Example 5, there are two methods by  
20 which the antigen of interest can be detected (directly and indirectly).

- a) Direct immunoassay, in which an antibody specific to the tail is required. This antibody is labeled with an element suitable for analysis by ICP-MS.
- b) Indirect immunoassay, in which an antibody (primary antibody) specific to the tail is required. In addition a secondary antibody specific to the primary  
25 antibody is labeled with an element suitable for analysis by ICP-MS.

Between 1-3 days after transfection of the cells, the growth media (typically 10%FBS, depending on cell-type) is removed and the mono-layer of attached cells are washed with 1xPBS three times. PBS is replaced with ice-cold methanol and the culture

5 dishes are incubated at  $-20^{\circ}\text{C}$  for 5 minutes. The methanol is removed and the cells are allowed to dry out completely. A blocking buffer (e.g. 10% horse serum, 1% BSA, 0.05% Tween-20, 1xPBS) is added to the culture dishes and the dishes are incubated for 1-2 hours at room temperature. In method a) an antibody specific to the tail is produced and labeled with an element that is suitable for analyzing with the  
10 ICP-MS. The antibody is diluted in blocking buffer and added to the culture dishes. The cells are exposed to the antibody mix for 2 hours at room temperature (or  $37^{\circ}\text{C}$ ). During this time, the element-tagged antibody binds the target protein through its tail. In method b) the antibody specific to the protein of interest is not labeled. The un-reacted primary antibody is washed away with blocking buffer. In method b) the  
15 element-labeled secondary antibody is diluted in blocking buffer and applied to the cells. The dishes are incubated for 1-2 hours at room temperature. The un-reacted secondary antibody is washed away with blocking buffer. Finally, in both methods, an acid solution (e.g. concentrated HCl) is added, to release and dissolve the tagging element. The dissolved element in acid is diluted with 10% HCl/1ppb Ir to provide an  
20 internal standard. The acid solution containing the tagging element is analyzed by ICP-MS to quantify the efficiency of the transfection. Culture dishes containing non-transfected cells cultured at the same time can be used as a negative control

An alternate variation of this Example involves using a 6xHIS-tagged construct<sup>TM</sup> (Invitrogen), where there is no need for specific antibodies. Cells transfected with  
25 6xHIS-tagged constructs are fixed with methanol, blocked with the blocking buffer and incubated for 2 hours with a solution containing nickel (e.g. Ni-NTA<sup>TM</sup>; Qiagen). The cells are washed to remove free nickel, acid degraded, and analyzed using ICP-MS for nickel content.

### 5 Example 7. Reporter assay

In the study of transcription factors, it is necessary to quantitate the levels of transcription. There are two methods by which discrete changes in the levels of transcription activity on a specific promoter (or enhancer elements) can be measured. Cultured cells are transfected with expression plasmids of interest along with equal  
10 amounts of plasmid containing the promoter of interest linked to a reporter gene (e.g. GFP). As in Example 5 there are two methods by which the antigen of interest can be detected (directly and indirectly).

a) Direct immunoassay, in which an antibody specific to the reporter is required.

This antibody is labeled with an element suitable for analysis by ICP-MS.

15 b) Indirect immunoassay, in which an antibody (primary antibody) specific to the reporter is required. In addition a secondary antibody specific to the primary antibody is labeled with an element suitable for analysis by ICP-MS.

Cultured cells are grown and transfected with conditions of interest. Upon analysis, the growth media is removed and the cells are washed with 1xPBS three times. PBS  
20 is replaced with ice-cold methanol and the culture dishes are incubated at  $-20^{\circ}\text{C}$  for 5 minutes. The methanol is removed and the cells are allowed to dry out completely. A blocking buffer (e.g. 10% horse serum, 1% BSA, 0.05% Tween-20, 1xPBS) is added to the culture dishes and the dishes are incubated for 1-2 hours at room temperature. In method a) an antibody specific to the reporter is labeled with an element, diluted in  
25 blocking buffer and added to the culture dishes. The cells are exposed to the antibody mix for 2 hours at room temperature (or  $37^{\circ}\text{C}$ ). During this time, the element-tagged antibody will bind the reporter. In method b) the antibody specific to the reporter is not labeled. In the next step, the un-reacted antibody is then washed away with blocking buffer. In method b) the element-labeled secondary antibody is diluted in



5 blocking buffer and applied to the cells. The dishes are incubated for 1-2 hours at room temperature. The un-reacted antibody is then washed away with blocking buffer. Finally, in both methods, an acid solution (e.g. concentrated HCl) is added, to release and dissolve the tagging element. The dissolved element in acid is diluted with 10% HCl/1ppb Ir to provide an internal standard. The acid solution containing  
10 the tagging element is analyzed by ICP-MS to quantify the protein of interest.

**Example 8. Detection of proteins after electrophoresis using tagged antibodies.**

A sample of proteins is diluted in 2xSDS sample buffer (1% SDS, 2% glycerol, 100mM Tris, pH6.8, 5%  $\beta$ -mercaptoethanol, 1% DTT, 1% PMSF, 0.2% leupeptin, 0.2% pepstatin) and exposed to electrophoresis on a 2-D or polyacrylamide  
15 gel (SDS-PAGE or N-PAGE) to separate the proteins. The proteins from the gel are transferred to nitrocellulose using a semi-dry transfer apparatus (or equivalent). The nitrocellulose is blocked for 1 hour at room temperature using a blocking buffer (e.g. 5% milk in 1xPBS). An element-tagged antibody that recognizes the target protein is added to blocking buffer and the nitrocellulose blot is exposed to the antibody-  
20 containing buffer for 2 hours at room temperature. Alternatively an un-labeled primary antibody that recognizes the target protein is used to bind the target protein, followed by washes with wash buffer, and then probing with a secondary anti-primary antibody that is labeled with an element. The nitrocellulose blot is washed three times with wash buffer (0.2%NP40 in 1xPBS). The protein in question is analyzed and  
25 quantified by laser ablation.

**Example 9. Detections of proteins after modification with 6xHIS-tag<sup>TM</sup> (Invitrogen) and separation by electrophoresis.**

This Example is similar to Example 8; however, the proteins in the sample are modified prior to electrophoresis so that they have an affinity for an element (e.g. the

- 5     6xHIS modification yields affinity to Nickel). The gel or blotting paper containing the separated proteins is washed with a solution containing an element (e.g. Ni) that is bound by the protein modification. The gel or blotting paper is analyzed by laser ablation (or direct excisions) and ICP-MS.

**Example 10. Size Exclusion Gel Filtration Immunoassay**

- 10             In this example, ICP-MS is used to detect the presence of a specific antigen. Accordingly, an antibody is tagged with an element (eg. Au, Eu, Ru, etc.) and is introduced into a sample containing the antigen of interest. The elemental-tagged antibody reacts specifically to the target antigen. The resulting tagged antigen-antibody complex is separated from un-reacted antibody using gel filtration (e.g.
- 15     HiPrep Sephacryl<sup>TM</sup>; Pharmacia) in a running buffer containing 1ppbIr. The eluate is collected in 0.5ml increments into a 96 well plate, diluted in acid, and analyzed by ICP-MS.

- Experimental results obtained according to this method for IgG analyte using Fab'-Au antibody are shown in Figure 5. In this experiment an IgG analyte is incubated with
- 20     an excess of Fab'-Au. The sample is run through a sephacryl S-200 column at a flow rate of 0.5ml/min, using a running buffer of 0.15M NaCl, 0.02M phosphate, pH 7.4, 1ppb Ir. The figure provides the detector response as a function of elution time (eluate number). The first peak observed (the heavier molecular weight) corresponds to the reacted complex, having an expected molecular weight of about 235 kDa. The
- 25     second peak corresponds to the unreacted tagged antibody having an expected molecular weight of about 85 kDa.

5     **Example 11. Detection and quantitation of elemental species.**

In this example, ICP mass spectrometry is used to measure a quantity of metal identified by an antibody which is specific for a given oxidation state, molecular form or species of a given metal. A target sample containing cationic metal ions is mixed with a molar excess of a metal-free chelator. A high affinity chelator is chosen to  
10    ensure that all cationic metal ions in the sample form a complex with the chelator. This solution is then incubated with an antibody, which is specific for the chelator-metal complex. This solution is treated to separate antibody-metal-chelator complexes from un-reacted antibody and the remainder of components in the sample, although it is important only that extraneous metals be removed from the sample.

15    Preferably, the antibody exhibits little or no ability to bind to the metal-free chelator, and exhibits a tight and specific binding of the metal-complex which is to be measured. Preferably, this binding affinity shows an equilibrium dissociation constant ( $K_D$ ) on the order of  $10^{-9}$  to  $10^{-8}$ M. The antibody used in such assays also is able to resist interference from other components contained in the sample, which is being  
20    assayed. The generation of such antibodies may be carried out according to the procedure described in Blake et al. (1998).

The solution containing the antibody-metal-chelator complexes is subject to standard ICP-MS/OES analysis. This approach removes the necessity for a chromatographic pre-separation and consequently improves the sample integrity. It also allows for  
25    simultaneous measurement of several metals/oxidation states/elemental species, the method being limited only by the number of antibodies introduced to the sample.

**Example 12. Detection and quantitation of elemental species using tagged antibodies.**

5           According to this Example, as in Example 11, antibodies specific for metal-chelator complexes are raised according to methods well known to those skilled in the art. The difference in this Example is the antibody is tagged with multiple atoms of a given tagging isotope, or a stoichiometric mixture of isotopic tags. This has two potential advantages. First, in the event that the target metal element is subject to  
10 interference in analysis through typical ICP-based interferences (for example argide ion isobaric interferences) tagging the antibody with a normally non-interfered tag allows for interference-free determination, resulting in improved detectability. Secondly, specific tags for various species of the same target element allows simultaneous measurement of various species (which would not be provided if the  
15 elemental tag were the innate target element itself, since the presence of that element in the spectrum would indicate only that one or more of the target species is present). A further advantage according to this approach is that tagging with multiple atoms of the same isotope allows for signal amplification proportional to the number of atoms of the same tagging isotope.

20   **Example 13. Simultaneous detection of numerous elemental species in a sample using tagged or untagged antibodies.**

          According to this example, as in Example 11 and 12, antibodies specific for metal-chelator complexes are raised according to methods well known to those skilled in the art. The difference in this Example is that two or more antibodies specific to  
25 different elemental species are incorporated, to allow for the simultaneous determination of different speciation states of the same or different elements (where each element is differentially tagged).

**Example 14. Immunoassay to detect Bovine Spongiform Encephalopathy (BSE) in animal products.**

5           The methods of Examples 1, 2, 3, 4, 5, 8, and/or 10 are employed to detect BSE in animal products. There are several monoclonal antibodies (15B3, Korth *et al.*, 1997; KG9, Laffling *et al.*, 2001; Bio-Rad Laboratories) that have been produced that target the prion protein PrP thought to be the infectious component responsible for the illness. Monoclonal antibodies specific to PrP are labeled with an element (eg. Au, 10 Eu, Ru, etc.) and used in immunoassays described in either Example 1, 2, 3, 4, 5, 8, and/or 10. Similar products known to be free of BSE would be used as a negative control. In a similar manner other diseases detected for by antibody can be screened for (e.g. HIV, HTLV, Rabies, etc.).

15           **Example 15. Immunoassay to detect ischemic markers in patients believed to have suffered a heart attack**

          The methods of Examples 1, 2, 3, 4, 5, 8, and/or 10 are employed to simultaneously detect multiple ischemic markers in human samples. Candidate markers include: CK-MB, myoglobin, Troponin I, hsp70, BCL2, Bax, IGF, TNF $\alpha$ , angiostatin II.

20           **Example 16. Method for Drug Discovery**

          In order to aid in drug discovery, animal cells or animal receptors are placed in multi-well plates. The molecule of interest is added (i.e. potential drug), as well as element-tagged antibody (or element tagged ligand) that recognizes the receptor. The potential drug is in competition with the antibody for adhesion to the receptor. 25 Unbound antibody is washed away, and the amount of bound antibody is determined by ICP-MS. This is inversely proportional to the effectiveness of the potential drug to recognize the receptor. If each well is provided with differently labeled antibodies, then by combining the contents of the wells, one can simultaneously assess the effectiveness of various drugs, or drug compositions by deconvoluting the resultant

5 data. Likewise, differently labeled antibodies for the same analyte can be produced and placed in corresponding wells of different plate (i.e. 10 differently labeled version of the antibody, each one placed in well 1, 1 in 10 plates). The plate contents are combined vertically, the reacted antibodies are separated and analyzed simultaneously, with de-convolution to determine the analyte concentration in the  
10 corresponding well of each plate.

**Example 17. Detection of tagged proteins using 2D gel and mass spectrometry.**

In this example, the ICP-DRC-MS technique is used in conjunction with the laser ablation of polyacrylamide gels containing proteins tagged by iron. It is well known that  $\text{ArN}^+$  and  $\text{ArO}^+$  interfere with  $^{54}\text{Fe}^+$  and  $^{56}\text{Fe}^+$ , respectively. To facilitate  
15 the method described in Example 11, it is essential to remove isobaric poly-atomic interferences from the iron isotopes. For example, the ratio of the mass spectrometric signals at  $m/z=54:m/z=56$  (where  $m/z$  indicates the mass-to-charge ratio of the ion) measured directly by ablation of the polyacrylamide gel containing a protein band tagged by iron was found to be 1.14 (whereas the expected value, based on the natural  
20 abundance of the iron isotopes, is 0.063). Utilizing ammonia as a reaction gas in the DRC environment, it is possible to eliminate  $\text{ArN}^+$  and  $\text{ArO}^+$  interferences by charge transfer reaction. This approach yielded the  $m/z=54:m/z=56$  ratio that approximated the expected  $^{54}\text{Fe}^+ / ^{56}\text{Fe}^+$  isotope ratio, by which agreement the determination of the tag iron can be confirmed. In addition, the precision of this measurement is  
25 significantly improved due to partial temporal equilibration of ions in the gaseous media of the reaction cell (see Bandura, D.R., *et al.* 2000).

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the

5 invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents, and parent applications are herein incorporated by  
10 reference in their entirety to the same extent as if each individual publication, patent or parent application was specifically and individually indicated to be incorporated by reference in its entirety.

5

## REFERENCES

Baldwin, G.S., Hollande, F., Yang, Z., Karelina, Y., Peterson, A. Strang, R, Fourmy, D., Neumann, G., Shulkes, A. 2001 Biologically active recombinant human progastrin <sub>6-80</sub> contains a tightly bound calcium ion. J. Biol. Chem 276: 7791

- 10 Bandura D.R., Baranov V.I. and Tanner S.D. 2000. Effect of collisional damping and reactions in a dynamic reaction cell on the precision of the isotope ratio measurements. J.Anal. At. Spectrom., 15:921.

- Baranov V.I., Tanner S.D. 1999 A dynamic reaction cell for inductively coupled  
15 plasma mass spectrometry (ICP-DRC-MS). Part I. The rf-field energy contribution in thermodynamics of ion-molecule reactions. J.Anal. At. Spectrom., 14:1133.

Barlett, P. A. et al, 1978 Synthesis of Water-Soluble Undecagold Cluster Compounds  
J. Am. Chem. Soc., 100: 5085

20

Binet M.R.B., Ma, R., McLeod, C. and Poole, R.K. 2001 Detection of zinc/cadmium binding proteins in *E. coli* by gel electrophoresis-laser ablation-inductively coupled plasma-mass spectrometry. Society for Experimental Biology Annual Meeting April2-6 C1.158 Canterbury, UK

25

Bio-Rad PLATELIA™ BSE test (DAS-ELISA)



- 5 Blake, D.A., Blake II, R.C., Khosraviani, M., Pavlov, A.R. 1998 Immunoassays for metal ions. *Analytica Chimica Acta* 376: 13

- Bordes, A.L., Schollborn, B., Limoges, B., and Degrand, C. 1999. Simultaneous detection of three drugs labelled by cationic metal complexes at a nafion-loaded  
10 carbon paste electrode. *Talanta* 48: 201.

- Bosslet, K., Hermentin, P., Seemann, G. 1999 Monoclonal antibody against complexed and non-complexed complexing agents for removing heavy metals from aqueous solutions and for analysis. US 5,907,034

15

- Chen , X. Smith, L., Bradbury, E. 2000 Site-specific mass tagging with stable isotopes in proteins for accurate and efficient protein identification. *Anal. Chem.* 72: 1134-1143.

- 20 Cotton, F.A. and Wilkinson, G. 1972. *Advanced Inorganic Chemistry*, Interscience Publishers 528-530.

- Darwish I.A. and Blake, D.A. 2001 One-step competitive immunoassay for cadmium ions: development and validation for environmental water samples. *Analytical*  
25 *Chemistry* 73: 1889

- 5 de Llano, J., Andreu, E., and Knecht, E. 1996. Use of Inductively Coupled Plasma-Mass Spectrometry for the Quantitation of the Binding and Uptake of Colloidal Gold-Low Density Lipoprotein Conjugates by Cultured Cells. *Analytical Biochem.* 243: 210-217.
- 10 de Llano, J., Andreu, E., Pastor, A., dela Guardia, M., Knecht, E. 2000. Electrothermal atomic absorption spectrometric diagnosis of familial hypercholesterolemia. *Anal. Chem.* 72: 2406-2413.
- Frackelton, Jr., Raymond, A., Eisen, H., Ross, 1985 A. Production and use of  
15 monoclonal antibodies to phosphotyrosine-containing proteins. US 4,543,439.
- Gillis, S 1983 Hybridoma antibody which inhibits interleukin 2 activity. US 4,411,993.
- 20 Hainfeld, J., Leone, R., Furuya, F., Powell, R. 1996 Small organometallic probes. US 5,521,289
- Harlow and Lane (Eds) 1988 *Antibodies: A Laboratory Manual*, Cold Spring Laboratory Press
- 25 Hinshaw, J., Toner, J., Reynolds, G., 1987 Fluorescent labels for immunoassay. US 4,637,988

5

Josel, H-P., Hoss, E., Ofenloch-Hahnle, B., Seidel, C., Upmeier, B., Wienhues, U-H.  
1999 Metal complexes with a charged linker. US 5,958,783

Kennet, McKearn, Bechtold (eds) 1980 Monoclonal antibodies hybridomas: A new  
10 dimension in biological analyses. Plenum Press.

Kohler, G and Milstein, C. 1975. Continuous cultures of fused cells secreting  
antibody of predefined specificity. Nature 256: 495.

15 Korth, C., Stierli, B., Streit, P., Moser, M., Schaller, O., Fischer, R., Schulz-Schaeffer,  
W., Kretzschmar, H., Raeber, A., Braun, U., Ehrensperger, F., Hornemann, S.,  
Glockshuber, R., Riek, R., Billerter, M., Wuthrich, K., and Oesch, B. 1997. Prion  
(PrP<sup>Sc</sup>)-specific epitope defined by a monoclonal antibody. Nature, 390(6655), 74-7.

20 Laffling, A.J., Baird, A., Birkett, C.R., and John, H.A. 2001. A monoclonal antibody  
that enables specific immunohistological detection of prion protein in bovine  
spongiform encephalopathy cases. Neurosci. Lett. 300(2), 99-102.

Nagaoka, M. and Maitani, T. 2000 Binding patterns of co-existing aluminium and  
25 iron to human serum transferrin studied by HPLC-high resolution ICP-MS. Analyst  
135: 1962-1965.

- 5 Qiu, J., and Song, J. F. 1996 A rapid polarographic immunoassay based on the anodic current of metal labelling. *Anal. Biochem.* 240: 13-16.

Segond von Banchet, G., and Heppelmann, B. 1995 Non-radioactive localization of substance P binding sites in rat brain and spinal cord using peptides labeled with 1.4  
10 nm gold particles. *J.Histochem.Cytochem.* 43: 821-827.

Tanner S.D., Baranov V.I. 1999 A dynamic reaction cell for inductively coupled plasma mass spectrometry (ICP-DRC-MS). Part II. Reduction of interferences produced within the cell. *JASMS*, 101083.

15

Tanner S.D., Baranov V.I. and Vollkopf U. 2000a A dynamic reaction cell for inductively coupled plasma mass spectrometry (ICP-DRC-MS). Part III. Optimization and analytical performance; *J.Anal. At. Spectrom.*, 15: 1261.

Tanner, S., Baranov, V. 2000b Bandpass reactive collision cell. US 6,140,638.

20

Wagenknecht, T., Berkowitz, J., Grassucci, R., Timerman. A.P., and Fleischer, S. 1994 Localization of calmodulin binding sites on the ryanodine receptor from skeletal muscle by electron microscopy. *Biophys. J.* 67: 2286-2295.

- 25 Wakabayashi, K., Sumi, Y., Ichikawa, Y., Sakato, Y., Mimuro, J., Aoki, N. 1990 Monoclonal antibody to human protein C: US 4,902,614

- 5 Wang, C.: 1984 Method of Tagged Immunoassay. US 4,454,233.

Wenzel, T., and Baumeister, W. 1995 Conformational constraints in protein degradation by the 20S proteasome. *Nature Structural Biol.* 2: 199-204.

- 10 Wind, M., Edler, M., Jakubowski, N., Linscheid, M., Wesch, H., Lehmann, W. 2001 Analysis of protein phosphorylation by capillary liquid chromatography coupled to element mass spectrometry with  $P^{31}$  detection and to electrospray mass spectrometry. *Anal. Chem.* 73: 29-35.

5    **We claim:**

1.            A method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with one of an analyte and analyte complex, comprising:

- 10            i)       combining the tagged biologically active material with one of the analyte and analyte complex,
- ii)       separating bound tagged biologically active material from unbound tagged material, and
- iii)       detecting and measuring the bound tag elements by one of an atomic mass and optical spectrometer having a source of ions or atomic ions.

15    2.            A method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with one of an analyte and analyte complex, comprising:

- 20            i)       combining the biologically active material with one of the analyte and analyte complex, wherein the biologically active material binds a transition element,
- ii)       introducing the transition element to the sample, and
- iii)       detecting and measuring the element by one of an atomic mass and optical spectrometer having a source of ions or atomic ions.

25    3.            A method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with an analyte in the sample, comprising:

- 5                    i)      directly tagging the biologically active material with a transition element,
- ii)      combining the tagged biologically active material with the analyte, where the biologically active material binds with the analyte,
- iii)     separating bound tagged biologically active material from
- 10                   unbound tagged material, and
- iv)     detecting and measuring the bound tag elements by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

4.                   A method for the detection and measurement of an element in a

15                   sample, where a primary biologically active material binds with an analyte in the sample, and the measured element is a tag on a secondary biologically active material that binds to the primary biologically active material, comprising:

- i)      combining the primary biologically active material with an analyte in a sample, where the primary biologically active material
- 20                   binds with the analyte,
- ii)     separating bound biologically active material from unbound biologically active material,
- iii)     directly tagging the secondary biologically active material with a transition element,
- 25                   iv)     introducing the tagged secondary biologically active material into the sample where the secondary biologically active material binds with the primary biologically active material,

5 v) separating bound tagged biologically active material from unbound tagged material, and

vi) detecting and measuring the bound tag elements by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

10 5. A method for the detection and measurement of an element in a sample, where a primary biologically active material binds with an analyte in the sample, and a secondary biologically active molecule binds with the primary biologically active material, and the measured element is a tag on a tertiary biologically active material that binds to the secondary biologically active material,  
15 comprising:

i) combining the primary biologically active material with an analyte in a sample, where the primary biologically active material binds with the analyte,

20 ii) separating bound biologically active material from unbound biologically active material,

iii) introducing the secondary biologically active material in the sample, where the secondary biologically active material binds with the primary biologically active material,

25 iv) separating bound biologically active material from unbound biologically active material,

v) directly tagging the tertiary biologically active material with a transition element,



- 5 vi) introducing the tagged tertiary biologically active material into the sample where the tagged tertiary biologically active material binds with the secondary biologically active material,
- vii) separating bound tagged biologically active material from unbound tagged material, and
- 10 viii) detecting and measuring the bound tag elements by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.
6. A method for the detection and measurement of an element of an elemental species in a sample, where an antibody specific to the chelated elemental species binds to the chelated elemental species, comprising:
- 15 i) chelating the elemental species,
- ii) introducing the antibody into the sample,
- iii) separating the antibody bound chelated elemental species complexes from the sample, and
- 20 iv) detecting and measuring an element of the elemental species contained in the removed complexes by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.
7. A method for the detection and measurement of an element in a sample including an elemental species, where the measured element is a tag on an antibody specific to the chelated elemental species, comprising:
- 25 i) chelating the elemental species,
- ii) tagging the antibody with a transition element,

- 5                   iii)     introducing the tagged antibody into the sample where the  
tagged antibody binds with the chelated elemental species,
- iv)     separating tagged antibody bound chelated elemental species  
from the sample, and
- v)     detecting and measuring an element contained in the removed  
10               complexes by one of an atomic mass and optical spectrometer having  
a source of atoms or atomic ions.

8.               The method of claim 7 wherein the measured element is an element of  
the elemental species.

9.               The method of claim 7 wherein the measured element is a tag on an  
15               antibody specific to the chelated elemental species and an element in the elemental  
species.

10.              A method for the detection and measurement of an element in a  
sample, where the measured element is a tag on an analyte in a sample, comprising:

- i) tagging the analyte with a transition element,
- 20               ii) electrophorescing the sample containing the tagged analyte, and
- iii) detecting and measuring the element by one of an atomic mass and  
optical spectrometer having a source of atoms or atomic ions.

11.              A method for the detection and measurement an element in a sample  
where the measured element is a tag on a biologically active material that binds with  
25               an analyte in a sample, comprising:

- i) binding the analyte with a biologically active material, wherein the  
biologically active material binds a transition element,

- 5                   ii) electrophorescing the sample containing the tagged analyte,
- iii) introducing the transition element to the electrophoresced sample,
- and
- iv) detecting and measuring the element by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

10   12.           A method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with an analyte in a sample, comprising:

- i)     binding the analyte with the biologically active material, wherein the biologically active material binds a transition element,
- 15               ii)     introducing the transition element to the sample; wherein the element tags the biologically active material, and
- iii)    detecting and measuring the element by one of an atomic mass and optical spectrometer having a source of atoms or atomic ions.

13               A method of claim 12 wherein the analyte is a cell.

20   14.           A method for the detection and measurement of an element in a sample, where the measured element is a tag on a biologically active material that binds with an analyte in a sample, comprising:

- i)     tagging the biologically active material with a transition element,
- 25               ii)     electrophorescing the sample containing the analyte,
- iii)    introducing the tagged biologically active material into the sample containing the analyte, and

- 5                   iv)    detecting and measuring the element by one of an atomic mass  
and optical spectrometer having a source of atoms or atomic ions.

15.               A method for the detection and measurement of an element in a  
sample, where a primary biologically active material binds with an analyte in the  
sample, and the measured element is a tag on a secondary biologically active material  
10   that binds to the primary biologically active material , comprising:

- i)    electrophorescing the sample containing the analyte,  
                  ii)    introducing the primary biologically active material into the  
sample where the primary biologically active material binds with the  
analyte,  
15               iii)    tagging the secondary biologically active material with a  
transition element,  
                  iv)    introducing the tagged secondary biologically active material  
into the sample, where the tagged secondary biologically active  
material binds with the primary biologically active material, and  
20               v)    detecting and measuring the element by one of an atomic mass  
and optical spectrometer having a source of atoms or atomic ions.

16.               The method of any of claims 1, 3, 4, 5, 7, 8, 9, 14, or 15 wherein the  
tagged biologically active material is a commercially available product.

17.               The method of any of claims 1 through 16 wherein the source of atoms  
25   or atomic ions is selected from a group consisting of inductively coupled plasma,  
graphite furnace, microwave induced plasma, glow discharge, capacitively coupled  
plasma, electrospray, MALDI and corona.

- 5 18. The method of any of claims 1 through 17 wherein the source of atoms or atomic ions is an inductively coupled plasma source.
19. The method of any of claims 1 through 18 wherein the step of detecting and measuring uses an optical spectrometer.
20. The method of any of claims 1 through 19 wherein the step of  
10 detecting and measuring uses a mass spectrometer.
21. The method of any of claims 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14 , 15, 16, 17, 18, 19 or 20 wherein the element is an isotope or ion.
22. The method of any of claims 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 wherein the element is selected from a group consisting of  
15 the noble metals, lanthanides, rare earth elements, gold, silver, platinum, rhodium, iridium and palladium.
23. The method of claim 22 wherein the element is one of gold and silver.
24. The method of any of claims 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 wherein the step of tagging involves covalently  
20 coupling the element to one of the biologically active material and analyte.
25. The method according to any of claims 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 wherein the biologically active material is selected from a group consisting of an antibody, antigen, hormone, growth factor, receptor, protein and nucleic acid.
- 25 26. The method of any of claims 1, 2, 3, 4, 5, 7, 8, 9 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 wherein the tag includes more than one element.

5     27.             The method of any of claims 1, 2, 3, 4, 5, 7, 8, 9 10, 11, 12, 13, 14, 15,  
16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 wherein the tag includes more than one  
isotope.

28.             The method of any of claims 1, 2, 3, 4, 5, 7, 8, 9 10, 11, 12, 13, 14, 15,  
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27 wherein the tag includes more than one  
10     atom of an isotope.

29.             The method of any of claims 1, 2, 3, 4, 5, 7, 8, 9 10, 11, 12, 13, 14, 15,  
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 wherein the tag includes a different  
number of atoms of each isotope.

30.             The method of any of claims 1 through 29 comprising an additional  
15     step of introducing two or more biologically active materials or analytes having  
distinguishable elemental tags into a sample of interest for simultaneous  
determination.

31.             The method according to any of claims 1 through 30 comprising an  
additional step of sample introduction, wherein the sample introduction includes laser  
20     ablation.

32.             The method according to claim 31 wherein the sample introduction  
includes laser ablation of polyacrylamide or agarose gels containing biologically  
active materials or analytes tagged by at least one element.

33.             The method according to claim 32 wherein the sample introduction  
25     includes laser ablation of polyacrylamide or agarose gels containing biologically  
active materials or analytes tagged by atoms of at least one element having an un-  
natural isotopic composition.

5    34.            The method according to any of claims 31 through 33 wherein the sample introduction includes laser ablation of animal tissue samples.

35.            The method according to any of claims 31 through 34 wherein the sample introduction includes laser ablation of cell cultures.

36.            A system of detection and measurement of molecules according to any  
10 of claims 1 through 35.

37.            Use of one of an atomic mass and optical spectrometer for the detection and measurement of the element of any of claims 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36.

15    38.            Use of one of an atomic mass and optical spectrometer for the detection and measurement of the elemental species of any of claims 6, 8 or 9.




Figure 1






Figure 2

Protein sepharase A immunoassay with human IgG and F'ab-Au  
(Average of three independent experiments)  
50 $\mu$ L of sample diluted in 1mL of 10%HCL with 1ppb Ir




Figure 3




Figure 4




Figure 5

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/01815

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 G01N33/58 G01N33/532

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 205 952 A (CAIS MICHAEL) 3 June 1980 (1980-06-03)	1-5, 16-30, 37, 38
Y	column 3, line 2 - column 11, line 30; examples 2, 3A, 21	6-15, 31-35
X	US 4 454 233 A (WANG CHIA-GEE) 12 June 1984 (1984-06-12) cited in the application	1-5, 16-30, 37, 38
Y	abstract	6-15, 31-35
	column 3, line 44 - column 4, line 53 column 6, line 1 - column 7, line 55; claims	
	---	
	---/---	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*S\* document member of the same patent family

Date of the actual completion of the international search

8 April 2002

Date of mailing of the international search report

24/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Luis Alves, D

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/01815

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 022 876 A (ANBAR MICHAEL) 10 May 1977 (1977-05-10)	1-5, 16-30, 37,38
Y	abstract  column 2, line 10 -column 6, line 40 ---	6-15, 31-35
Y	BLAKE, D A ET AL: "Immunoassays for metal ions" ANALYTICA CHIMICA ACTA, vol. 376, 1998, pages 13-19, XP001063361 abstract page 14, left-hand column, paragraph 2 -page 15, right-hand column, paragraph 1 ---	6-9,12, 13
Y	US 5 907 034 A (BOSSLET KLAUS ET AL) 25 May 1999 (1999-05-25) abstract ---	6-9,12, 13
P,Y	DARWISH I A ET AL: "ONE-STEP COMPETITIVE IMMUNOASSAY FOR CADMIUM IONS: DEVELOPMENT AND VALIDATION FOR ENVIRONMENTAL WATER SAMPLES" ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. COLUMBUS, US, vol. 73, no. 8, 15 April 2001 (2001-04-15), pages 1889-1895, XP001030286 ISSN: 0003-2700 cited in the application abstract; figure 1 ---	6-9,12, 13
Y	NEILSEN J L ET AL: "Laser ablation inductively coupled plasma-mass spectrometry in combination with gel electrophoresis: A new strategy for speciation of metal binding serum proteins." SPECTROCHIMICA ACTA PART B ATOMIC SPECTROSCOPY, vol. 53, no. 2, February 1998 (1998-02), pages 339-345, XP001068501 ISSN: 0584-8547 abstract  --- -/--	10,11, 14,15, 31-35

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 01/01815

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EVANS R DOUGLAS ET AL: "A method for characterization of humic and fulvic acids by gel electrophoresis laser ablation inductively coupled plasma mass spectrometry." JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY., vol. 15, no. 2, February 2000 (2000-02), pages 157-161, XP001068410 ISSN: 0267-9477 abstract	10,11, 14,15, 31-35
P,X	--- ZHANG CHAO ET AL: "A novel combination of immunoreaction and ICP-MS as a hyphenated technique for the determination of thyroid-stimulating hormone (TSH) in human serum." JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, vol. 16, no. 12, December 2001 (2001-12), pages 1393-1396, XP001068414 December, 2001 ISSN: 0267-9477 the whole document	1-35,37, 38
T	--- BARANOV, V.I. ET AL: "A sensitive and quantitative element-tagged immunoassay with ICPMS detection" ANALYTICAL CHEMISTRY, vol. 74, no. 7, 1 April 2002 (2002-04-01), pages 1629-1636, XP001068480 the whole document -----	1-35,37, 38

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 36

Claim 36 concerns a system but does not contain any features characterising said system. The features necessary to make the system suitable or especially adapted for the performance of the methods referred to in the claim are recited neither in the claim nor in the description.

Thus, claim 36 lacks clarity to such an extent that a meaningful search is not possible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 01/01815

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4205952	A	03-06-1980	IL 49685 A	31-10-1978
			AU 517300 B2	23-07-1981
			AU 2543777 A	30-11-1978
			CA 1100036 A1	28-04-1981
			DE 2724486 A1	22-12-1977
			FR 2353854 A1	30-12-1977
			GB 1550540 A	15-08-1979
			IT 1079695 B	13-05-1985
			JP 1359288 C	13-01-1987
			JP 52148620 A	10-12-1977
			JP 61028100 B	28-06-1986
US 4454233	A	12-06-1984	US 4436826 A	13-03-1984
US 4022876	A	10-05-1977	NONE	
US 5907034	A	25-05-1999	DE 4007079 A1	12-09-1991
			US 5908790 A	01-06-1999
			AT 127848 T	15-09-1995
			AU 651962 B2	11-08-1994
			AU 7264491 A	12-09-1991
			CA 2037664 A1	08-09-1991
			DE 59106448 D1	19-10-1995
			DK 446730 T3	22-01-1996
			EP 0446730 A1	18-09-1991
			ES 2077700 T3	01-12-1995
			GR 3017741 T3	31-01-1996
			IE 910750 A1	11-09-1991
			JP 3065370 B2	17-07-2000
			JP 4218390 A	07-08-1992
			KR 210720 B1	15-07-1999
			PT 96945 A , B	31-10-1991